hlb therapeutics nk treatment rgn-259

Neurophet Inc., a South Korean startup developing artificial intelligence-powered medical solutions for brain diseases, is striving to make a breakt...

HLB Co. announced on May 17 that it has submitted a new drug application (NDA) to the US Food and Drug Administration (FDA) for the approval of Rivo...

Amorepacific Corp.'s cosmetic brand Laneige announced on Tuesday that it is accelerating its global business expansion by entering the UK and Middle...

South Korea’s Celltrion Inc. is speeding up global clinical trials of its biosimilar of the multiple sclerosis (MS) treatment Ocrevus (active ...

South Korean new drug developer Kainos Medicine Inc. announced on Friday that it had signed a technology transfer agreement with Chinese pharmaceuti...

Armed with artificial intelligence and big data technologies, Asleep hopes to find the best treatment for sleep-deprived people around the world wit...

South Korea's Ministry of Food and Drug Safety announced on Wednesday that it has approved the cognitive therapy software "WELT-I" developed by We...

South Korean companies are standing out in the global competition to develop chimeric antigen receptor T-cell (CAR-T) treatments, dubbed "dream" a...

South Korean anti-cancer immunotherapy company Vaxcell-Bio Therapeutics announced on Friday that its natural killer (NK) cell therapy, Vax-NK/HCC, h...

South Korea's pharmaceutical company HLB Therapeutics Co. announced on Thursday that it has started patient administration of "RGN-259," a treatment...

HLB Cell, a subsidiary of HLB Life Science Co., which specializes in the development of cell therapy products, announced on April 4 that it succeede...

JW Pharmaceutical, a drug company based in South Korea, has received its first patent for a hair loss treatment that is currently in development. Th...

South Korea's microneedle maker Raphas Co. is expediting its entry into the American pharmaceutical market after entering the country's cosmetics se...

NKGen Biotech, the US affiliate of South Korea's natural killer (NK) cell therapy developer NK Max, on Friday said it signed a letter of intent (LOI) ...

With South Korea setting new lows in birth rate every year, PharmaResearch on Wednesday said it will adopt an unprecedented system of childbirth and...

Toray Advanced Materials Korea Inc. announced on Monday the acquisition of Hanmee Entec Co., Ltd., the industry's longest-running water treatment fa...

Prestige Biopharma, a biopharmaceutical company in South Korea, announced on Thursday that their pancreatic cancer antibody drug, PBP1510 (Ulenistam...

South Korean pharmaceutical company Daewoong Pharmaceutical announced on Tuesday that it has received marketing authorization from Chile's National ...

South Korea's OliX Pharmaceuticals has received approval from Australia's Human Research Ethics Committees (HREC) to plan a phase 1 clinical trial o...

South Korea's GC Biopharma Corp. announced on Thursday that it will start developing a flu vaccine based on messenger ribonucleic acid (mRNA).The dr...

Samsung Bioepis Co., a South Korean biosimilar firm, announced on Sunday that it has recently launched a new biosimilar drug called SB11 for the tre...

South Korea’s health and drug safety authority has cleared Somzz to treat patients with sleep disorders, a dynamic move that is expected to vi...

Vaxcell-Bio Therapeutics, a South Korean company specializing in anti-cancer immunotherapy, announced on Wednesday its partnership with Cellid Co. t...

South Korea's biohealth company HK inno.N said on Tuesday that its gastroesophageal reflux disease (GERD) treatment K-CAB (active ingredient: tegopr...

SK Plasma Co. Ltd., a South Korean company specializing in the production of plasma derivatives from human plasma, is expanding its product portfoli...

South Korean pharmaceuticals firm Hanall Biopharma Co. is investing in Interon Laboratories, a US biotech firm that finds and develops treatments fo...

South Korea's HLB Co. announced on Thursday that the combination therapy of its drug candidate rivoceranib and Jiangsu Hengrui Pharmaceuticals Co., ...

South Korea's bio firm GC Cell announced on Wednesday that its US affiliate Artiva Biotherapeutics has received fast-track designation from the US F...

South Korean drugmaker Hanmi Pharmaceutical Co.’s neutropenia agent, Rolvedon (eflapegrastim-xnst), is forecast to achieve about $10 million i...

South Korea's biotech companies Bridge Biotherapeutics Inc. and Pinotbio on Thursday said they will jointly develop new antibody-drug conjugates (AD...